BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sookoian S, Flichman D, Scian R, Rohr C, Dopazo H, Gianotti TF, Martino JS, Castaño GO, Pirola CJ. Mitochondrial genome architecture in non-alcoholic fatty liver disease. J Pathol 2016;240:437-49. [PMID: 27577682 DOI: 10.1002/path.4803] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. Antioxidants (Basel) 2021;10:174. [PMID: 33530432 DOI: 10.3390/antiox10020174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
2 Boland ML, Oldham S, Boland BB, Will S, Lapointe JM, Guionaud S, Rhodes CJ, Trevaskis JL. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction. World J Gastroenterol 2018; 24(16): 1748-1765 [PMID: 29713129 DOI: 10.3748/wjg.v24.i16.1748] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
3 Sookoian S, Flichman D, Garaycoechea ME, San Martino J, Castaño GO, Pirola CJ. Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage. Hepatol Commun 2018;2:654-65. [PMID: 29881817 DOI: 10.1002/hep4.1184] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
4 Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349-364. [PMID: 29740166 DOI: 10.1038/s41575-018-0009-6] [Cited by in Crossref: 197] [Cited by in F6Publishing: 196] [Article Influence: 98.5] [Reference Citation Analysis]
5 Sookoian S, Pirola CJ. Cell-free DNA methylation as liquid biopsy for the assessment of fibrosis in patients with nonalcoholic steatohepatitis: a gap between innovation and implementation. Hepatobiliary Surg Nutr. 2017;6:117-121. [PMID: 28503559 DOI: 10.21037/hbsn.2017.01.07] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
6 Li Y, Sundquist K, Wang X, Zhang N, Hedelius A, Sundquist J, Memon AA. Association of Mitochondrial DNA Copy Number and Telomere Length with Prevalent and Incident Cancer and Cancer Mortality in Women: A Prospective Swedish Population-Based Study. Cancers (Basel) 2021;13:3842. [PMID: 34359743 DOI: 10.3390/cancers13153842] [Reference Citation Analysis]
7 Middleton P, Vergis N. Mitochondrial dysfunction and liver disease: role, relevance, and potential for therapeutic modulation. Therap Adv Gastroenterol 2021;14:17562848211031394. [PMID: 34377148 DOI: 10.1177/17562848211031394] [Reference Citation Analysis]
8 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int J Mol Sci 2021;22:4459. [PMID: 33923295 DOI: 10.3390/ijms22094459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Leonetti S, Herzog RI, Caprio S, Santoro N, Tricò D. Glutamate-Serine-Glycine Index: A Novel Potential Biomarker in Pediatric Non-Alcoholic Fatty Liver Disease. Children (Basel) 2020;7:E270. [PMID: 33291552 DOI: 10.3390/children7120270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020;69:1483-91. [DOI: 10.1136/gutjnl-2019-318811] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 35.0] [Reference Citation Analysis]
11 Liu Y, Zhang W, Wu X, Gong J. Foxo3a-dependent Bim transcription protects mice from a high fat diet via inhibition of activation of the NLRP3 inflammasome by facilitating autophagy flux in Kupffer cells. Oncotarget 2017;8:34258-67. [PMID: 28427239 DOI: 10.18632/oncotarget.15946] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
12 Sookoian S, Pirola CJ, Valenti L, Davidson NO. Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology. Hepatology 2020;72:330-46. [PMID: 32170962 DOI: 10.1002/hep.31229] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 22.0] [Reference Citation Analysis]
13 Lee LN, Huang CT, Hsu CL, Chang HC, Jan IS, Liu JL, Sheu JC, Wang JT, Liu WL, Wu HS, Chang CN, Wang JY. Mitochondrial DNA Variants in Patients with Liver Injury Due to Anti-Tuberculosis Drugs. J Clin Med 2019;8:E1207. [PMID: 31412578 DOI: 10.3390/jcm8081207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Sookoian S, Pirola CJ. Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse. Ann Hepatol 2018;17:182-6. [PMID: 29469051 DOI: 10.5604/01.3001.0010.8631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Pirola CJ, Sookoian S. Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity. World J Gastroenterol 2018; 24(15): 1601-1615 [PMID: 29686467 DOI: 10.3748/wjg.v24.i15.1601] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 29] [Article Influence: 12.7] [Reference Citation Analysis]
16 Luo C, Sun H, Peng J, Gao C, Bao L, Ji R, Zhang C, Zhu W, Jin Y. Rosmarinic acid exerts an antagonistic effect on nonalcoholic fatty liver disease by regulating the YAP1/TAZ-PPARγ/PGC-1α signaling pathway. Phytother Res 2021;35:1010-22. [PMID: 32914480 DOI: 10.1002/ptr.6865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Sookoian S, Pirola CJ. Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology. Clin Mol Hepatol. 2020;26:461-475. [PMID: 32906228 DOI: 10.3350/cmh.2020.0136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
18 Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2017;23:1-12. [PMID: 28268262 DOI: 10.3350/cmh.2016.0109] [Cited by in Crossref: 95] [Cited by in F6Publishing: 87] [Article Influence: 23.8] [Reference Citation Analysis]
19 Sookoian S, Rohr C, Salatino A, Dopazo H, Fernandez Gianotti T, Castaño GO, Pirola CJ. Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease. Oncotarget 2017;8:22917-26. [PMID: 28206970 DOI: 10.18632/oncotarget.15286] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
20 Sookoian S, Pirola CJ. Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. Hepatobiliary Surg Nutr 2021;10:337-49. [PMID: 34159161 DOI: 10.21037/hbsn-20-270] [Reference Citation Analysis]
21 Pirola CJ, Garaycoechea M, Flichman D, Castaño GO, Sookoian S. Liver mitochondrial DNA damage and genetic variability of Cytochrome b - a key component of the respirasome - drive the severity of fatty liver disease. J Intern Med 2021;289:84-96. [PMID: 32634278 DOI: 10.1111/joim.13147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
22 Dornas W, Schuppan D. Mitochondrial oxidative injury: a key player in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2020;319:G400-11. [PMID: 32597705 DOI: 10.1152/ajpgi.00121.2020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
23 Sookoian S, Pirola CJ. Repurposing drugs to target nonalcoholic steatohepatitis. World J Gastroenterol 2019; 25(15): 1783-1796 [PMID: 31057294 DOI: 10.3748/wjg.v25.i15.1783] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
24 Gusdon AM, Hui Y, Chen J, Mathews CE, Qu S. Mitochondrial haplogroup G is associated with nonalcoholic fatty liver disease, while haplogroup A mitigates the effects of PNPLA3. Endocrinol Diabetes Metab 2021;4:e00187. [PMID: 33532620 DOI: 10.1002/edm2.187] [Reference Citation Analysis]
25 Chimienti G, Orlando A, Russo F, D'Attoma B, Aragno M, Aimaretti E, Lezza AMS, Pesce V. The Mitochondrial Trigger in an Animal Model of Nonalcoholic Fatty Liver Disease. Genes (Basel) 2021;12:1439. [PMID: 34573421 DOI: 10.3390/genes12091439] [Reference Citation Analysis]
26 Sookoian S, Pirola CJ. The nonalcoholic steatohepatitis metabotype: Imbalance of circulating amino acids and transamination reactions reflect impaired mitochondrial function. Hepatology. 2018;67:1177-1178. [PMID: 29205411 DOI: 10.1002/hep.29705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Malik AN, Simões ICM, Rosa HS, Khan S, Karkucinska-Wieckowska A, Wieckowski MR. A Diet Induced Maladaptive Increase in Hepatic Mitochondrial DNA Precedes OXPHOS Defects and May Contribute to Non-Alcoholic Fatty Liver Disease. Cells 2019;8:E1222. [PMID: 31597406 DOI: 10.3390/cells8101222] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
28 Viswanathan P, Sharma Y, Maisuradze L, Tchaikovskaya T, Gupta S. Ataxia telangiectasia mutated pathway disruption affects hepatic DNA and tissue damage in nonalcoholic fatty liver disease. Exp Mol Pathol 2020;113:104369. [PMID: 31917286 DOI: 10.1016/j.yexmp.2020.104369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
29 Mann JP, Raponi M, Nobili V. Clinical implications of understanding the association between oxidative stress and pediatric NAFLD. Expert Rev Gastroenterol Hepatol. 2017;11:371-382. [PMID: 28162008 DOI: 10.1080/17474124.2017.1291340] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
30 Zeng X, Yang J, Hu O, Huang J, Ran L, Chen M, Zhang Y, Zhou X, Zhu J, Zhang Q, Yi L, Mi M. Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling. Antioxid Redox Signal. 2019;30:163-183. [PMID: 29310441 DOI: 10.1089/ars.2017.7172] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 17.7] [Reference Citation Analysis]